C 08001

Drug Profile

C 08001

Alternative Names: C08001; Carvedilol CR INNOPHARMAX; Inno-C08001

Latest Information Update: 27 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator INNOPHARMAX
  • Class Antihypertensives; Carbazoles; Ethanolamines; Heart failure therapies; Ischaemic heart disorder therapies; Phenyl ethers; Propanolamines; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Alpha beta adrenergic receptor antagonists; Beta-adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Myocardial infarction
  • Preclinical Cardiovascular disorders

Most Recent Events

  • 27 Oct 2017 C 08001 is still in preclinical development for Cardiovascular disorders in Taiwan (Innopharmax pipeline, October 2017)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders in Taiwan (PO, Tablet)
  • 14 Oct 2015 Phase-III clinical trials in Myocardial infarction in Taiwan (PO) before October 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top